Article Detail - JF Part B
Billing and Coding: MolDX: Minimal Residual Disease Testing for Hematologic Cancers (A58997) - R8 - Effective July 11, 2024
Date Posted: November 14, 2024
This Local Coverage Article (LCA) has been revised under contractor numbers: 02102 (AK), 02202 (ID), 02302 (OR), 02402 (WA), 03102 (AZ), 03202 (MT), 03302 (ND), 03402 (SD), 03502 (UT), and 03602 (WY).
Effective Date: July 11, 2024
Summary of Changes:
Under Article Text added verbiage, "Mantle Cell Lymphoma" to the Indicated Uses and Limitations box. Under ICD-10 Codes that Support Medical Necessity Group 2: Codes added C83.10, C83.11, C83.12, C83.13, C83.14, C83.15, C83.16, C83.17, C83.18, and C83.19. This revision is effective for 7/11/2024.
Visit the Noridian Molecular Diagnostic Services webpage to view the Active MolDX LCDs or access it via the CMS MCD.